MedTrace Logo

Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma

NCT01249690 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2010-11-30

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the efficacy of PAD-regimen and TAD-regimen in newly diagnosed multiple myeloma(MM).

Conditions

Interventions

DRUG

Bortezomib,Pirarubicin,Dexamethasone

Bortezomib:1.3mg/m2,on day 1,4,8 and 11 of each 28 day cycle; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.

DRUG

Thalidomide,Pirarubicin,Dexamethasone

Thalidomide:200mg/d, everyday; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.

Sponsors & Collaborators

  • Zhejiang University

    collaborator OTHER

  • Peking University People's Hospital

    collaborator OTHER

  • Air Force Military Medical University, China

    collaborator OTHER

  • Xiangya Hospital of Central South University

    collaborator OTHER

  • Institute of Hematology & Blood Diseases Hospital, China

    collaborator OTHER

  • Union hospital of Fujian Medical University

    collaborator OTHER

  • Harbin Hematology and Oncology Institute

    collaborator OTHER

  • First Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • Beijing Jishuitan Hospital

    collaborator OTHER

  • Second Military Medical University

    lead OTHER

Principal Investigators

  • Jian Hou, PhD · Shanghai Changzheng Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2012-06-30
Completion
2014-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01249690 on ClinicalTrials.gov